QR Pharma Announces the Start of a Phase I Clinical Study for Bisnorcymserine
7/24/2012 9:59:52 AM
BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that it initiated the first human clinical trial of the company’s compound bisnorcymserine (BNC) to evaluate safety and tolerability in a cohort of older healthy adults. The study will be conducted by the NIA/NIH clinical research group under an NIH Clinical Trial Agreement; it is led by Dr. Dimitrios Kapogiannis of the NIA Intramural Research Program.
comments powered by